Cubicin clears FDA
Executive Summary
Cubist's Cubicin, formerly Cidecin (daptomycin for injection) is approved Sept. 12 for treatment of complicated skin and skin structure infections. An FDA "Talk Paper" notes it is the first cyclic lipopeptide antibacterial agent. Cubicin's priority action review date of June 20 had been extended three months after reformatting of data sets (1"The Pink Sheet" June 23, 2003, In Brief)...
You may also be interested in...
Cubist Boosts Cubicin Sales Reps, Will Detail 80% Of Vancomycin Prescribers
Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said
Chiron Tifacogin Needs One Pivotal Study For Community Acquired Pneumonia
Chiron will need only a single pivotal trial for approval of its tissue factor pathway inhibitor tifacogin as a treatment for severe community acquired pneumonia
Cubist Cubicin Marketing To Highlight Single Daily Dose Of Antibiotic
Cubist's Cubicin (daptomycin) will be promoted for its single daily dosing compared to traditional antibiotics administered at least twice daily